Compass Therapeutics Investor Presentation Deck

CTX-009 Phase 2 Results (Median follow-up of 12.1 months) 24 patients enrolled and dosed 1 patient remains on study Endpoint Overall Response Rate (ORR) Stable Disease (SD) Progression Free Survival (PFS) Overall Survival (OS) Duration of Response COMPASS THERAPEUTICS Value (95% CI) 37.5% 54.2% 9.4 m (5.4-11.1) 12.5 m (10.9 - NA) 6.9 m (3.5-NA) Number of previous systemic therapies Pts treated in the 2L [n=11] Pts treated in the 3L [n=13] ORR 7/11 (63.6%) 2/13 (15.4%) 19

View entire presentation